Development of Assays to Measure GNE Gene Potency and Gene Replacement in Skeletal Muscle
Journal of Neuromuscular Diseases · 2023
DOI: 10.3233/jnd-221596 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Neuromuscular Diseases, 2023. Verfasst von Deborah A Zygmunt und 6 weiteren Autor:innen. Beteiligte Einrichtung: Center for Gene Therapy, Abigail Wexner Research Institute, Nationwide Children's Hospital, Children's Drive, Columbus, OH, USA. Hauptthemen laut MEDLINE: Cytomegalovirus Infections, Muscle, Skeletal. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
GNE myopathy (GNEM) is a severe muscle disease caused by mutations in the UDP-GlcNAc-2-epimerase/ManNAc-6-kinase ( GNE ) gene, which encodes a bifunctional enzyme required for sialic acid (Sia) biosynthesis.
Objective
To develop assays to demonstrate the potency of AAV gene therapy vectors in making Sia and to define the dose required for replacement of endogenous mouse Gne gene expression with human GNE in skeletal muscles.
Methods
A MyoD -inducible Gne -deficient cell line, Lec3MyoD I , and a GNE- deficient human muscle cell line, were made and tested to define the potency of various AAV vectors to increase binding of Sia-specific lectins, including MAA and SNA. qPCR and qRT-PCR methods were used to quantify AAV biodistribution and GNE gene expression after intravenous delivery of AAV vectors designed with different promoters in wild-type mice.
Results
Lec3 cells showed a strong deficit in MAA binding, while GNE –/– MB135 cells did not. Overexpressing GNE in Lec3 and Lec3MyoD I cells by AAV infection stimulated MAA binding in a dose-dependent manner. Use of a constitutive promoter, CMV, showed higher induction of MAA binding than use of muscle-specific promoters (MCK, MHCK7). rAAVrh74.CMV. GNE stimulated human GNE expression in muscles at levels equivalent to endogenous mouse Gne at a dose of 1×10 13 vg/kg, while AAVs with muscle-specific promoters required higher doses. AAV biodistribution in skeletal muscles trended higher when CMV was used as the promoter, and this correlated with increased sialylation of its viral capsid.
Conclusions
Lec3 and Lec3MyoD I cells work well to assay the potency of AAV vectors in making Sia. Systemic delivery of rAAVrh74.CMV. GNE can deliver GNE gene replacement to skeletal muscles at doses that do not overwhelm non-muscle tissues, suggesting that AAV vectors that drive constitutive organ expression could be used to treat GNEM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Gene Therapy, Abigail Wexner Research Institute, Nationwide Children's Hospital, Children's Drive, Columbus, OH, USA.
- Department of Genetics, Yale University School of Medicine, New Haven, CT, USA.
- Department of Pediatrics, The Ohio State University College of Medicine, Columbus, OH, USA.
Zitieren
APA
Zygmunt, D. A., Lam, P., Ashbrook, A., Koczwara, K., Lek, A., Lek, M., & Martin, P. T. (2023). Development of Assays to Measure GNE Gene Potency and Gene Replacement in Skeletal Muscle. Journal of Neuromuscular Diseases. https://doi.org/10.3233/jnd-221596
Vancouver
Zygmunt DA, Lam P, Ashbrook A, Koczwara K, Lek A, Lek M, et al. Development of Assays to Measure GNE Gene Potency and Gene Replacement in Skeletal Muscle. Journal of Neuromuscular Diseases. 2023. doi:10.3233/jnd-221596
BibTeX
@article{Zygmunt2023,
author = {Zygmunt, Deborah A and Lam, Patricia and Ashbrook, Anna and Koczwara, Katherine and Lek, Angela and Lek, Monkol and Martin, Paul T},
title = {Development of Assays to Measure GNE Gene Potency and Gene Replacement in Skeletal Muscle},
journal = {Journal of Neuromuscular Diseases},
year = {2023},
doi = {10.3233/jnd-221596}
}
EUVIMED